Global In Situ Hybridization Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

List of Tables

The global demand for In Situ Hybridization Market is presumed to reach the market size of nearly USD 8.24 BN by 2030 from USD 2.9 BN in 2022 with a CAGR of 13.95% under the study period 2023 - 2030.

In Situ Hybridization or ISH is a technique used in molecular biology and genetics to detect and localize specific DNA or RNA sequences in cells or tissues. It involves using labelled probes, which are complementary to the target sequence of interest, to bind and hybridize with the nucleic acids in the sample being studied. ISH can be used to identify the presence or absence of specific genetic sequences in cells or tissues, as well as to determine the location of those sequences within the cell or tissue. This technique is widely used in research to study gene expression, chromosomal abnormalities, and viral infections.

Market Dynamics:

The development of personalized medicine is dependent on the ability to accurately identify and diagnose genetic mutations and alterations. ISH is a critical tool for this process, enabling researchers and clinicians to detect specific nucleic acid sequences in cells or tissues, which can inform treatment decisions and improve patient outcomes. The field of genomics is rapidly expanding, driven by advances in sequencing technologies and the growing availability of genetic data. ISH is a key tool for studying gene expression and the location of specific genes within the genome, making it an essential technique for genomics research. The prevalence of diseases, such as cancer and neurological disorders, is increasing globally. ISH is a critical tool for diagnosing and treating chronic diseases, enabling clinicians to accurately identify genetic mutations and alterations that contribute to disease development and progression. The development of new probes and detection methods for ISH is driving innovation in the field, enabling researchers and clinicians to detect smaller quantities of nucleic acids with higher accuracy and sensitivity.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of in situ hybridization. The growth and trends of in situ hybridization industry provide a holistic approach to this study.

Market Segmentation:

This section of the in situ hybridization market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Technology

Fluorescent In Situ Hybridization (FISH)
Chromogenic In Situ Hybridization (CISH)

By Probe

By Product

Instruments
Kits & Probes
Software
Services

By Application

Cancer
Cytogenetics
Developmental Biology
Infectious Diseases
Others

By End-Use

Research & Diagnostic Laboratories
CROs
Academic Institutes
Others

Regional Analysis

This section covers the regional outlook, which accentuates current and future demand for the In Situ Hybridization market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the in situ hybridization market include Thermo Fisher Scientific Inc., Abbott (Abbott Molecular), PerkinElmer Inc., BioView, Agilent Technologies Inc., Merck KGaA, Bio-Rad Laboratories Inc., Oxford Gene Technology IP Limited, Leica Biosystems Nussloch GmbH, F. Hoffman-La Roche Limited, NeoGenomics Laboratories Inc., Advanced Cell Diagnostics Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

Product Code: VMR112110579

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . IN SITU HYBRIDIZATION - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Technology
- 3.7.2 Market Attractiveness Analysis By Probe
- 3.7.3 Market Attractiveness Analysis By Product
- 3.7.4 Market Attractiveness Analysis By Application
- 3.7.5 Market Attractiveness Analysis By End-use
- 3.7.6 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5. IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL IN SITU HYBRIDIZATION MARKET ANALYSIS BY TECHNOLOGY

6.1 Overview by Technology
6.2 Historical and Forecast Data
6.3 Analysis by Technology
6.4 Fluorescent In Situ Hybridization (FISH) Historic and Forecast Sales by Regions
6.5 Chromogenic In Situ Hybridization (CISH) Historic and Forecast Sales by Regions

7 . GLOBAL IN SITU HYBRIDIZATION MARKET ANALYSIS BY PROBE

7.1 Overview by Probe
7.2 Historical and Forecast Data
7.3 Analysis by Probe
7.4 DNA Historic and Forecast Sales by Regions
7.5 RNA Historic and Forecast Sales by Regions

8 . GLOBAL IN SITU HYBRIDIZATION MARKET ANALYSIS BY PRODUCT

8.1 Overview by Product
8.2 Historical and Forecast Data
8.3 Analysis by Product
8.4 Instruments Historic and Forecast Sales by Regions
8.5 Kits & Probes Historic and Forecast Sales by Regions
8.6 Software Historic and Forecast Sales by Regions
8.7 Services Historic and Forecast Sales by Regions

9 . GLOBAL IN SITU HYBRIDIZATION MARKET ANALYSIS BY APPLICATION

9.1 Overview by Application
9.2 Historical and Forecast Data
9.3 Analysis by Application
9.4 Cancer Historic and Forecast Sales by Regions
9.5 Cytogenetics Historic and Forecast Sales by Regions
9.6 Developmental Biology Historic and Forecast Sales by Regions
9.7 Infectious Diseases Historic and Forecast Sales by Regions
9.8 Others Historic and Forecast Sales by Regions

10 . GLOBAL IN SITU HYBRIDIZATION MARKET ANALYSIS BY END-USE

10.1 Overview by End-use
10.2 Historical and Forecast Data
10.3 Analysis by End-use
10.4 Research & Diagnostic Laboratories Historic and Forecast Sales by Regions
10.5 CROs Historic and Forecast Sales by Regions
10.6 Academic Institutes Historic and Forecast Sales by Regions
10.7 Others Historic and Forecast Sales by Regions

11 . GLOBAL IN SITU HYBRIDIZATION MARKET ANALYSIS BY GEOGRAPHY

11.1. Top Company Share Analysis
11.2. Introduction
11.3. North America Sales Analysis
- 11.3.1. Overview, Historic and Forecast Sales Analysis
- 11.3.2. North America By Segment Sales Analysis
- 11.3.3. North America By Country Sales Analysis
- 11.3.4. United State Sales Analysis
- 11.3.5. Canada Sales Analysis
- 11.3.6. Mexico Sales Analysis
11.4. Europe Sales Analysis
- 11.4.1. Overview, Historic and Forecast Sales Analysis
- 11.4.2. Europe by Segment Sales Analysis
- 11.4.3. Europe by Country Sales Analysis
- 11.4.4. United Kingdom Sales Analysis
- 11.4.5. France Sales Analysis
- 11.4.6. Germany Sales Analysis
- 11.4.7. Italy Sales Analysis
- 11.4.8. Russia Sales Analysis
- 11.4.9. Rest Of Europe Sales Analysis
11.5. Asia Pacific Sales Analysis
- 11.5.1. Overview, Historic and Forecast Sales Analysis
- 11.5.2. Asia Pacific by Segment Sales Analysis
- 11.5.3. Asia Pacific by Country Sales Analysis
- 11.5.4. China Sales Analysis
- 11.5.5. India Sales Analysis
- 11.5.6. Japan Sales Analysis
- 11.5.7. South Korea Sales Analysis
- 11.5.8. Australia Sales Analysis
- 11.5.9. Rest Of Asia Pacific Sales Analysis
11.6. Latin America Sales Analysis
- 11.6.1. Overview, Historic and Forecast Sales Analysis
- 11.6.2. Latin America by Segment Sales Analysis
- 11.6.3. Latin America by Country Sales Analysis
- 11.6.4. Brazil Sales Analysis
- 11.6.5. Argentina Sales Analysis
- 11.6.6. Peru Sales Analysis
- 11.6.7. Chile Sales Analysis
- 11.6.8. Rest of Latin America Sales Analysis
11.7. Middle East & Africa Sales Analysis
- 11.7.1. Overview, Historic and Forecast Sales Analysis
- 11.7.2. Middle East & Africa by Segment Sales Analysis
- 11.7.3. Middle East & Africa by Country Sales Analysis
- 11.7.4. Saudi Arabia Sales Analysis
- 11.7.5. UAE Sales Analysis
- 11.7.6. Israel Sales Analysis
- 11.7.7. South Africa Sales Analysis
- 11.7.8. Rest Of Middle East And Africa Sales Analysis

12 . COMPETITIVE LANDSCAPE OF THE IN SITU HYBRIDIZATION COMPANIES

12.1. In Situ Hybridization Market Competition
12.2. Partnership/Collaboration/Agreement
12.3. Merger And Acquisitions
12.4. New Product Launch
12.5. Other Developments

13 . COMPANY PROFILES OF IN SITU HYBRIDIZATION INDUSTRY

13.1. Company Share Analysis
13.2. Market Concentration Rate
13.3. Thermo Fisher Scientific Inc.
- 13.3.1. Company Overview
- 13.3.2. Company Revenue
- 13.3.3. Products
- 13.3.4. Recent Developments
13.4. Abbott (Abbott Molecular)
- 13.4.1. Company Overview
- 13.4.2. Company Revenue
- 13.4.3. Products
- 13.4.4. Recent Developments
13.5. PerkinElmer Inc.
- 13.5.1. Company Overview
- 13.5.2. Company Revenue
- 13.5.3. Products
- 13.5.4. Recent Developments
13.6. BioView
- 13.6.1. Company Overview
- 13.6.2. Company Revenue
- 13.6.3. Products
- 13.6.4. Recent Developments
13.7. Agilent Technologies Inc.
- 13.7.1. Company Overview
- 13.7.2. Company Revenue
- 13.7.3. Products
- 13.7.4. Recent Developments
13.8. Merck KGaA
- 13.8.1. Company Overview
- 13.8.2. Company Revenue
- 13.8.3. Products
- 13.8.4. Recent Developments
13.9. Bio-Rad Laboratories Inc.
- 13.9.1. Company Overview
- 13.9.2. Company Revenue
- 13.9.3. Products
- 13.9.4. Recent Developments
13.10. Oxford Gene Technology IP Limited
- 13.10.1. Company Overview
- 13.10.2. Company Revenue
- 13.10.3. Products
- 13.10.4. Recent Developments
13.11. Leica Biosystems Nussloch GmbH
- 13.11.1. Company Overview
- 13.11.2. Company Revenue
- 13.11.3. Products
- 13.11.4. Recent Developments
13.12. F. Hoffman-La Roche Limited
- 13.12.1. Company Overview
- 13.12.2. Company Revenue
- 13.12.3. Products
- 13.12.4. Recent Developments
13.13. NeoGenomics Laboratories Inc.
- 13.13.1. Company Overview
- 13.13.2. Company Revenue
- 13.13.3. Products
- 13.13.4. Recent Developments
13.14. Advanced Cell Diagnostics Inc.
- 13.14.1. Company Overview
- 13.14.2. Company Revenue
- 13.14.3. Products
- 13.14.4. Recent Developments

*Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies